Related Experiment Video
Updated: Jul 13, 2025
Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
Published on: February 24, 2023
Advancement of anti-LAG-3 in cancer therapy
Abstract:
Immune checkpoint inhibitors have effectively transformed the treatment of many cancers, particularly those highly devastating malignancies. With their widespread popularity, the drawbacks of immune checkpoint inhibitors are also recognized, such as drug resistance and immune-related systematic side effects. Thus, it never stops investigating novel immune checkpoint inhibitors. Lymphocyte Activation Gene-3 (LAG-3) is a well-established co-inhibitory receptor that performs negative regulation on immune responses. Recently, a novel FDA-approved LAG-3 blocking agent, together with nivolumab as a new combinational immunotherapy for metastatic melanoma, brought LAG-3 back into focus. Clinical data suggests that anti-LAG-3 agents can amplify the therapeutic response of other immune checkpoint inhibitors with manageable side effects. In this review, we elucidate the intercellular and intracellular mechanisms of LAG-3, clarify the current understanding of LAG-3 in the tumor microenvironment, identify present LAG-3-associated therapeutic agents, discuss current LAG-3-involving clinical trials, and eventually address future prospects for LAG-3 inhibitors.
Insights
Novel immune checkpoint inhibitors targeting Lymphocyte Activation Gene-3 (LAG-3) show promise in enhancing cancer immunotherapy. Anti-LAG-3 agents, combined with other treatments, amplify therapeutic responses with manageable side effects.
Area of Science:
- Oncology
- Immunology
- Pharmacology
Background:
- Immune checkpoint inhibitors (ICIs) have revolutionized cancer therapy but face challenges like drug resistance and immune-related side effects.
- Lymphocyte Activation Gene-3 (LAG-3) is a key co-inhibitory receptor regulating immune responses.
- Recent FDA approval of a LAG-3 inhibitor in combination therapy has renewed interest in LAG-3's therapeutic potential.
Purpose of the Study:
- To review the intercellular and intracellular mechanisms of LAG-3.
- To clarify the role of LAG-3 within the tumor microenvironment.
- To identify current LAG-3 therapeutic agents and clinical trials, and discuss future prospects.
Main Methods:
- Literature review of intercellular and intracellular LAG-3 mechanisms.
- Analysis of LAG-3's role in the tumor microenvironment.
- Identification and discussion of current LAG-3-associated therapeutic agents and clinical trials.
Main Results:
- LAG-3 acts as a negative regulator of immune responses.
- Anti-LAG-3 agents can enhance the efficacy of other ICIs.
- Combination therapies involving LAG-3 inhibitors demonstrate manageable side effects.
Conclusions:
- LAG-3 is a promising target for novel cancer immunotherapies.
- LAG-3 inhibitors hold potential for improving treatment outcomes in various cancers.
- Further research into LAG-3-based therapies is warranted to overcome current limitations.
More Related Videos
07:55Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer
Published on: January 17, 2025
07:43Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients
Published on: September 25, 2018
